Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC-302 in Detrusor Underactivity with Overactive Bladder
NCT03175029Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in detrusor underactivity (DU) and overactive bladder (OAB) comparing TAC-302 with Placebo (2 arms). Primary endpoints: Bladder Contractility Index at 12 weeks and Projected Isovolumetric Pressure 1 at 12 weeks. Started Sep 2017; status: completed.
02
Drugs
TAC-302
03
Conditions
detrusor underactivity (DU)overactive bladder (OAB)
Beyond the preview
Go deeper on NCT03175029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175029.